Skip to main content
An official website of the United States government
Principal Investigator
Khalid Matin
Awardee Organization

Virginia Commonwealth University
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

VCU Massey Cancer Center Minority/Underserved NCI Community Oncology Research Program

Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center (Massey) will serve as the primary component site for an NCI Community Oncology Research Program (NCORP) Community Site (UG1 award in partnership with nine collaborating community affiliate sites in the Commonwealth of Virginia. This proposal emphasizes the urban and rural populations available to VCU/Massey’s NCORP. This community-based NCORP, focused on increasing the availability of NCI clinical research trials to all populations, was initially funded in 1990 as a Community Clinical Oncology Program and has been continuously funded since. The VCU/Massey NCORP has affiliations with six Research Bases (Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, Wake Forest NCORP Research Base, and University of Rochester NCORP Research Base). This proposal focuses on the urban and rural populations available to VCU/Massey’s NCORP and on accruing significant numbers of participants in cancer control and prevention, treatment/imaging, and cancer care delivery clinical research studies. This application describes VCU/Massey’s NCORP collaborations with the Research Bases as well as the working relationships between the primary site’s investigators, research staff, support personnel, and the affiliate sites. Accordingly, the specific aims of this proposal are to: (1) Increase the overall enrollment to NCI-approved studies, with participation representative of the catchment area, with a strong focus on cancer control research (CCR), cancer prevention research (CPR), and cancer care delivery research (CCDR), in addition to cancer treatment research (CTR); (2) Collaborate with the NCORP Research Bases by (a) providing insight into clinical significance during concept development, (b) identifying care imbalances in local populations served by VCU Massey’s NCORP that could be studied, and (c) providing input on feasibility concept and protocol development; (3) Exceed the required annual minimum participation in CCDR protocols; (4) Participate in biospecimen collection for biobanks that serve as scientific resources for NCORP Research Bases; and (5) Participate in NCORP initiatives to document screening efforts for clinical trial enrollment and to address differences in cancer health outcomes. The proposed revision to extend the VCU/Massey NCORP award is relevant to NCI’s mission as it will continue to advance scientific knowledge and help all people live longer, healthier lives.

Publications

  • Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England journal of medicine. 2019 Jun 20;380(25):2395-2405. Epub 2019 Jun 3. PMID: 31157962
  • Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute. 2021 Apr 6;113(4):390-399. PMID: 32986828
  • Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023 Mar 2;388(9):813-823. PMID: 36856617
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2018 Jul 12;379(2):111-121. Epub 2018 Jun 3. PMID: 29860917
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2015 Nov 19;373(21):2005-14. Epub 2015 Sep 27. PMID: 26412349